FDA Approves Evolocumab (Repatha) to Prevent CV Events FDA Approves Evolocumab (Repatha) to Prevent CV Events

Evolocumab becomes the first PCSK9 inhibitor approved in the US to reduce outcomes including MI, stroke, and coronary revascularization, as well as lipid lowering.FDA Approvals

Source: Medscape Medical News Headlines - December 2, 2017 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news